Analysts expect tightening of competition in Russian pharma market in

The level of competition in the Russian pharmaceutical market
will significantly tighten next year, as local drugmakers plan to
overtake global producers in the segment of public procurements,
reports The Pharma Letter’s local correspondent.  

One of such companies is Biocad, which is trying to get its
Ivlizi (divozilimab), a treatment for multiple sclerosis, to be
included in the list of vital drugs. That will allow Biocad to
participate…

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source